Key facts
- It has raised $230.0M across 3 recorded rounds; the latest was PIPE ($130.0M) in Apr 2024.
- Acrivon Therapeutics has filed 2 Form Ds with the SEC, most recently Nov 2021 ($100.0M sold to 13 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Acrivon Therapeutics
Create free account
No card required
Funding rounds
3 roundsApr 2024PIPE$130.0M▮
Nov 2021Early Stage VC (Series B)$100.0M▮
About Acrivon Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Acrivon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Acrivon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Acrivon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.